The results of 394 consecutive cases of knee joint radiation synovectomy (radiosynoviorthesis) using 90Y

Miszczyk, Marcin; Jochymek, B.; Miszczyk, Leszek; Matysiakiewicz, Jacek; Spindel, Jerzy; Jabłońska, Iwona; Mrozek, Tomasz; Chrobok, Adam; Tomasik, Patryk; Zakrzewski, T; Tukiendorf, Andrzej

doi:10.1007/s12149-019-01418-w

Cited by 15 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies in adult patients with RA highlighted a better response to RS in an earlier stage of the disease and at a younger age [22,23]. Comparison in our study response to RS in older (> 10 years old) and younger (< 10 years old) children revealed only difference in the Colorado scale 6 weeks after the RS as better in the younger age group.…”

Section: Discussionsupporting

confidence: 50%

“…According to Jahanier et al [21], one year from the RS patients with RA achieved a significant improvement in the pain VAS, functional mobility, joint tenderness and joint oedema in 76% of cases. In the experience of Miszczyk et al [22] after 6 months of observation, 47.6% of patients experienced partial pain relief (the scale: 0 -no pain, 1 -partial pain reduction, 2 -pain comparable to before the RS), while in 33% total pain relief was achieved.…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

The use of radiosynovectomy in patients with juvenile idiopathic arthritis. Assessment of treatment efficacy and safety

Gazda¹,

Ćwikła²,

Kołodziejczyk³

et al. 2021

Reumatologia

View full text Add to dashboard Cite

Objectives: The aim of the study was to evaluate the usefulness of knee joint radiosynovectomy (RS) in patients suffering from juvenile idiopathic arthritis (JIA). Material and methods: One hundred RS procedures performed in 58 patients with JIA in average age 10.4 years were evaluated. Results: After 6 weeks, a decrease in the number of cases with joint pain from 90.3% to 29%, with joint oedema from 100% to 74.5%, with joint exudate from 100% to 60.6%, with gait disorders from 19.4% to 3.2%, with joint mobility disorders from 51.1% to 26.6% in the RS cases was observed. A reduction of the score in the Colorado scale from 10.9 to 4.66, in the pain visual analogue scale (VAS) from 50 to 10, in the illness VAS assessed by the patient/parent from 69.9 to 32.4, in the illness VAS assessed by the physician from 68.8 to 36.9 was observed. Six months after the RS procedure, a reduction in the number of cases with joint pain from 89.5% prior to the procedure to 29.5%, with oedema from 100% to 58.3%, with exudate from 100% to 46.9%, with gait disorders from 20% to 2.1%, with joint motility disorders from 51.1% to 26.1% was achieved. The score in the Colorado scale was reduced from 10.9 to 4.04, in the pain VAS from 40 to 0, in the illness VAS assessed by the patient/parent from 69.7 to 27.9, in the illness VAS assessed by the physician from 68.8 to 32.4. In ultrasound examinations, the greatest improvement compared to the initial condition was recorded in the 6 th month after the RS. Radiosynovectomy was positively evaluated by parents and patients in 34 anonymous surveys. Early and late observations (average 1473 days) did not show lesions at the isotope injection site, and no neoplastic lesions were observed. Conclusions: Radiosynovectomy is a valuable therapeutic option for local treatment in patients with JIA.

show abstract

Section: Discussionsupporting

confidence: 50%

Section: Discussionmentioning

confidence: 95%

The use of radiosynovectomy in patients with juvenile idiopathic arthritis. Assessment of treatment efficacy and safety

Gazda¹,

Ćwikła²,

Kołodziejczyk³

et al. 2021

Reumatologia

View full text Add to dashboard Cite

show abstract

“…The radiation of the distributed nanoparticles to the surrounding normal tissue is still unavoidable. Moreover, multiple injections of radioactive material might cause local skin atrophy, necrosis, or infection (Miszczyk et al, 2020 ). Therefore, the selection of radionuclides and the optimization of treatment are crucial.…”

Section: Discussionmentioning

confidence: 99%

Energy Conversion-Based Nanotherapy for Rheumatoid Arthritis Treatment

Wang

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is characterized by synovial hyperplasia and cartilage/bone destruction, which results in a high disability rate on human health and a huge burden on social economy. At present, traditional therapies based on drug therapy still cannot cure RA, in accompany with the potential serious side effects. Based on the development of nanobiotechnology and nanomedicine, energy conversion-based nanotherapy has demonstrated distinctive potential and performance in RA treatment. This strategy employs specific nanoparticles with intrinsic physiochemical properties to target lesions with the following activation by diverse external stimuli, such as light, ultrasound, microwave, and radiation. These nanoagents subsequently produce therapeutic effects or release therapeutic factors to promote necrotic apoptosis of RA inflammatory cells, reduce the concentration of related inflammatory factors, relieve the symptoms of RA, which are expected to ultimately improve the life quality of RA patients. This review highlights and discusses the versatile biomedical applications of energy conversion-based nanotherapy in efficient RA treatment, in together with the deep clarification of the facing challenges and further prospects on the final clinical translations of these energy conversion-based nanotherapies against RA.

show abstract

“…In a study by Miszczyk et al of 394 RSOs of the knee with [ 90 Y]yttrium colloid, including 73 RA cases, pain relief was observed in 81% at 6 months (33% with complete pain relief) and in 87% at 1 year. The likelihood of pain relapse in RA cases was 15% at 6 months and 27% at 12 months [ 44 ]. In a multicenter study by Liepe et al, 99 knee RSOs (68 with [ 90 Y]yttrium colloid, 15 with [ 32 P]phosphorus colloid, and 16 with [ 188 Re]rhenium colloid) were compared with 46 intraarticular GC injections.…”

Section: Indications For Radiosynoviorthesismentioning

confidence: 99%

The EANM guideline for radiosynoviorthesis

Kampen¹,

Boddenberg-Pätzold

Fischer³

et al. 2021

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose Radiosynoviorthesis (RSO) using the intraarticular application of beta-particle emitting radiocolloids has for decades been used for the local treatment of inflammatory joint diseases. The injected radiopharmaceuticals are phagocytized by the superficial macrophages of the synovial membrane, resulting in sclerosis and fibrosis of the formerly inflamed tissue, finally leading to reduced joint effusion and alleviation of joint pain. Methods The European Association of Nuclear Medicine (EANM) has written and approved these guidelines in tight collaboration with an international team of clinical experts, including rheumatologists. Besides clinical and procedural aspects, different national legislative issues, dosimetric considerations, possible complications, and side effects are addressed. Conclusion These guidelines will assist nuclear medicine physicians in performing radiosynoviorthesis. Since there are differences regarding the radiopharmaceuticals approved for RSO and the official indications between several European countries, this guideline can only give a framework that must be adopted individually.

show abstract

The results of 394 consecutive cases of knee joint radiation synovectomy (radiosynoviorthesis) using 90Y

Cited by 15 publications

References 24 publications

The use of radiosynovectomy in patients with juvenile idiopathic arthritis. Assessment of treatment efficacy and safety

The use of radiosynovectomy in patients with juvenile idiopathic arthritis. Assessment of treatment efficacy and safety

Energy Conversion-Based Nanotherapy for Rheumatoid Arthritis Treatment

The EANM guideline for radiosynoviorthesis

Contact Info

Product

Resources

About